Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (URGN)
NASDAQ:URGN
Holding URGN?
Track your performance easily
URGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.78 - $20.70
Previous CloseN/A
Volume157.75K
Average Volume (3M)430.26K
Market Cap
$443.94M
Enterprise Value$419.47M
Total Cash (Recent Filing)$21.36M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Mar 13, 2025EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.14
Shares Outstanding42,199,413
10 Day Avg. Volume454,978
30 Day Avg. Volume430,262
Standard Deviation0.23
R-Squared0.06
Alpha-0.00879
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.97
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue4.69
Enterprise Value/Gross Profit5.72
Enterprise Value/Ebitda-4.57
Forecast
1Y Price Target
$49.50Price Target Upside381.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Urogen Pharma News
PremiumCompany Announcements
UroGen Pharma Highlights RTGel® Platform and Growth Plans
PremiumCompany Announcements
UroGen Pharma Reports Q3 Results and Drug Progress
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessUGN-102 demonstrated an 82.3% 12-month duration of response by Kaplan-Meier estimate in patients who had achieved a complete response at three months after the first instillation.
Market PotentialThe UGN-102 target market may be far larger than the JELMYTO market, potentially exceeding $5 billion annually.
Regulatory ApprovalThe FDA accepted the NDA for UGN-102 with standard review and set a PDUFA date of June 13th, 2025, with a high likelihood of approval.
Bears Say
Financial PerformanceFinancial results reported—top- and bottom-line miss, reduced near-term revenue outlook.
Market RisksRisks include inability to achieve projected market penetration due to higher-than-projected levels of competition and other factors.
Revenue ExpectationsThe company now expects 2024 revenue to be just below the previous $95-102MM guidance range.
---
Ownership Overview
2.40% Insiders
2.52% Mutual Funds
0.23% Other Institutional Investors
88.98% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
URGN FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest stock price was $9.78 and its highest was $20.70 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is $443.94M.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Mar 13, 2025 which is in 54 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on Nov 06, 2024. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.817 by $0.267.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is -0.74.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 42,199,413 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.817. Following the earnings report the stock price went up 0.246%.
Which hedge fund is a major shareholder of Urogen Pharma?
Among the largest hedge funds holding Urogen Pharma’s share is Wildcat Capital Management, Llc. It holds Urogen Pharma’s shares valued at 6M.
---
Urogen Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$49.50 (381.99% Upside)
$49.50 (381.99% Upside)
Blogger Sentiment
Bullish
URGN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.12%
12-Months-Change
Fundamentals
Return on Equity
-452.20%
Trailing 12-Months
Asset Growth
55.94%
Trailing 12-Months
Company Description
Urogen Pharma
UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. Its pipeline includes upper tract urothelial carcinoma, low grade non muscle invasive bladder cancer, carcinoma in situ of the bladder, and overactive bladder. The company was founded by Asher Holzer in 2004 and is headquartered in New York, NY.
---
URGN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a strong focus on the future potential of UGN-102 with its NDA acceptance and significant clinical progress. While JELMYTO showed notable revenue growth, the company faces challenges with gross to net erosion and increased net loss. The sentiment is balanced with a leaning towards optimism due to the strategic initiatives and strong cash position to support future growth.Read More>---
URGN Stock 12 Month Forecast
Average Price Target
$49.50
▲(381.99% Upside)
Technical Analysis
Assertio Therapeutics
―
Avadel Pharmaceuticals
―
Karyopharm Therapeutics
―
MannKind
―
ADMA Biologics
―
Arvinas Holding Company
―
Best Analysts Covering URGN
1 Year
1 Year Success Rate
3/15 ratings generated profit
1 Year Average Return
-13.89%
reiterated a buy rating 2 months ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -13.89% per trade.
---